Trials / Terminated
TerminatedNCT00486720
Phase IIa Vorinostat (MK0683, Suberoylanilide Hydroxamic Acid (SAHA)) Study in Lower Risk Myelodysplastic Syndromes (0683-064)
A Randomized Phase IIa Study of Vorinostat in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is to evaluate the efficacy, safety and tolerability of vorinostat in patients with lower risk Myelodysplastic Syndrome (MDS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | vorinostat | vorinostat 400 mg by mouth (P.O.) capsules once daily (q.d.). Treatment in 21 day cycles for up to 8 cycles. |
| DRUG | vorinostat | vorinostat 200 mg by mouth (P.O.) capsules three times daily (t.i.d.). Treatment in 21 day cycles for up to 8 cycles. |
Timeline
- Start date
- 2007-06-01
- Primary completion
- 2009-07-01
- Completion
- 2009-07-01
- First posted
- 2007-06-15
- Last updated
- 2015-07-03
- Results posted
- 2010-06-22
Source: ClinicalTrials.gov record NCT00486720. Inclusion in this directory is not an endorsement.